Last edition
News about "Glenmark Therapeutics "
Glenmark Therapeutics Unveils Olopatadine Hydrochloride Ophthalmic Solution
Glenmark Therapeutics has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 percent (OTC) as compared to the active ingredient in Pataday Twice Daily Relief.
Glenmark Therapeutics | 20/08/2024 | By Aishwarya | 118
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members